Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 84.55% | 61.93% | 27.56% | 24.14% | -208.18% |
| Total Depreciation and Amortization | -12.41% | -5.88% | 77.65% | 157.35% | 730.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.40% | -32.87% | 324.37% | 183.12% | 984.83% |
| Change in Net Operating Assets | -106.90% | 8.77% | 49.87% | -549.10% | 380.65% |
| Cash from Operations | 67.02% | 60.62% | 40.43% | -14.94% | -39.90% |
| Capital Expenditure | 89.80% | -- | 107.37% | 64.58% | -176.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 1,885.81% | 155.22% | 7,522.86% |
| Cash from Investing | -100.01% | -- | 1,292.50% | 154.35% | 6,548.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 55,444.44% | -- | -- | -100.00% | -99.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -265.31% | -- | 100.00% | 94.52% | 96.63% |
| Cash from Financing | 5,314.61% | -- | -100.01% | 94.50% | -100.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.11% | -48.51% | 771.93% | 72.54% | -50.20% |